Surrozen (SRZN) Gains from Investment Securities (2020 - 2026)
Surrozen (SRZN) posted quarterly Gains from Investment Securities of $41.1 million for Q1 2026, up 201.2% year-over-year from $13.6 million in Q1 2025, and down 29.85% quarter-over-quarter from $58.6 million in Q4 2025.
Powered by 
Analysis
Surrozen (SRZN) Gains from Investment Securities (2020 - 2026) Analysis & Trends
Surrozen's Gains from Investment Securities history runs 7 years deep, the most recent figure standing at $41.1 million for Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 201.2% year-over-year to $41.1 million; the TTM figure through Mar 2026 stood at $104.6 million (up 272.28% YoY), while the FY2025 annual figure was $22.8 million, up 28.03% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $41.1 million, down from $58.6 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $58.6 million in Q4 2025, with the low at -$42.9 million in Q2 2024.
- The 5-year median for Gains from Investment Securities is -$83000.0 (2023), against an average of $2.1 million.
- The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities soared 15475.78% in 2024, then tumbled 64582.54% in 2025.
- Surrozen's Gains from Investment Securities stood at -$921000.0 in 2022, then soared by 86.1% to -$128000.0 in 2023, then jumped by 15475.78% to $19.7 million in 2024, then soared by 197.75% to $58.6 million in 2025, then slipped by 29.85% to $41.1 million in 2026.
- Business Quant data shows SRZN's Gains from Investment Securities at $41.1 million in Q1 2026, $58.6 million in Q4 2025, and $20.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Surrozen | 263.35 Mn | 263.35 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -20.36 Mn |
| Mar 31, 2026 | 41.11 Mn |
| Dec 31, 2025 | 58.60 Mn |
| Sep 30, 2025 | 20.92 Mn |
| Jun 30, 2025 | -16.07 Mn |
| Mar 31, 2025 | -40.62 Mn |
| Dec 31, 2024 | 19.68 Mn |
| Sep 30, 2024 | 3.19 Mn |
| Jun 30, 2024 | -42.94 Mn |
| Mar 31, 2024 | 63,000.00 |
| Dec 31, 2023 | -128,000.00 |
| Sep 30, 2023 | -83,000.00 |
| Jun 30, 2023 | -265,000.00 |
| Mar 31, 2023 | 265,000.00 |
| Dec 31, 2022 | -921,000.00 |
| Sep 30, 2022 | -50,000.00 |
| Jun 30, 2022 | -422,000.00 |
| Mar 31, 2022 | -6.50 Mn |
| Dec 31, 2021 | -7,000.00 |
| Sep 30, 2021 | -64,000.00 |